ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
-5.04%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$497M
AUM Growth
+$497M
(+36%)
Cap. Flow
+$71.1M
Cap. Flow
% of AUM
14.31%
Top 10 Holdings %
Top 10 Hldgs %
61.21%
Holding
306
New
59
Increased
87
Reduced
47
Closed
53
Top Buys
| 1 |
Cytokinetics
CYTK
|
$29M |
| 2 |
Protagonist Therapeutics
PTGX
|
$28.4M |
| 3 |
BridgeBio Pharma
BBIO
|
$18.1M |
| 4 |
Roivant Sciences
ROIV
|
$14.4M |
| 5 |
Royalty Pharma
RPRX
|
$12.1M |
Top Sells
| 1 |
TECX
Tectonic Therapeutic, Inc. Common Stock
TECX
|
$59.3M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$43.3M |
| 3 |
MACK
Merrimack Pharmaceuticals, Inc.
MACK
|
$13.3M |
| 4 |
Perspective Therapeutics
CATX
|
$6.05M |
| 5 |
Sarepta Therapeutics
SRPT
|
$4.21M |
Sector Composition
| 1 | Healthcare | 85.86% |
| 2 | Financials | 1.87% |
| 3 | Industrials | 0.23% |
| 4 | Utilities | 0.18% |
| 5 | Materials | 0.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Protagonist Therapeutics
PTGX
$3.67B
| $55.6M | 10.49% | 1,603,932 +818,277 | +104% | +$28.4M |
|
|
2
Cytokinetics
CYTK
$4.23B
| $46.3M | 8.73% | 853,862 +534,352 | +167% | +$29M |
|
|
3
Roivant Sciences
ROIV
$8.15B
| $43.9M | 8.28% | 4,150,009 +1,358,139 | +49% | +$14.4M |
|
4
Alpha Architect 1-3 Month Box ETF
BOXX
$7.91B
| $37.9M | 7.15% | 351,482 +33,362 | +10% | +$3.6M |
|
|
5
BridgeBio Pharma
BBIO
$9.89B
| $32M | 6.05% | 1,264,570 +714,766 | +130% | +$18.1M |
|
|
6
Royalty Pharma
RPRX
$15.6B
| $31.2M | 5.88% | 1,181,332 +460,031 | +64% | +$12.1M |
|
7
Keros Therapeutics
KROS
$618M
| $25.1M | 4.74% | 548,916 +210,673 | +62% | +$9.63M |
|
8
Immunovant
IMVT
$2.56B
| $12.6M | 2.38% | 476,543 +415,780 | +684% | +$11M |
|
9
Arbutus Biopharma
ABUS
$711M
| $10.2M | 1.92% | 3,289,260 +1,215,077 | +59% | +$3.75M |
|
10
Merck
MRK
$210B
| $9.38M | 1.77% | 75,750 +75,450 | +25,150% | +$9.34M |
|
11
Rezolute
RZLT
$619M
| $8.88M | 1.68% | +2,063,962 | New | +$8.88M |
|
12
Solid Biosciences
SLDB
$427M
| $8.05M | 1.52% | 1,420,422 +1,217,218 | +599% | +$6.9M |
|
13
Edgewise Therapeutics
EWTX
$1.51B
| $7.86M | 1.48% | 436,608 +255,697 | +141% | +$4.61M |
|
|
PCSC
14
Perceptive Capital Solutions Corp Class A Ordinary Shares
PCSC
$117M
| $7.55M | 1.42% | +750,000 | New | +$7.55M |
|
15
Ascendis Pharma
ASND
$11.8B
| $6.99M | 1.32% | 51,263 +2,679 | +6% | +$365K |
|
|
TECX
16
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $5.88M | 1.11% | 356,878 -3,597,979 | -91% | -$59.3M |
|
17
uniQure
QURE
$896M
| $5.48M | 1.03% | 1,222,676 +929,826 | +318% | +$4.17M |
|
18
Absci
ABSI
$357M
| $5.23M | 0.99% | 1,698,529 +1,111,545 | +189% | +$3.42M |
|
19
Viking Therapeutics
VKTX
$3.04B
| $4.84M | 0.91% | 91,227 +76,826 | +533% | +$4.07M |
|
20
Alkermes
ALKS
$4.78B
| $4.74M | 0.89% | 196,577 +39,977 | +26% | +$963K |
|
|
BBOT
21
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$708M
| $4.13M | 0.78% | 404,138 +638 | +0.2% | +$6.52K |
|
22
AnaptysBio
ANAB
$569M
| $3.9M | 0.74% | 155,799 +154,799 | +15,480% | +$3.88M |
|
|
CERE
23
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $3.82M | 0.72% | 93,350 +69,091 | +285% | +$2.83M |
|
24
Crinetics Pharmaceuticals
CRNX
$2.92B
| $3.35M | 0.63% | +74,850 | New | +$3.35M |
|
25
SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$42.1B
| $2.98M | 0.56% | 32,500 | – | – |
|